207_Combined course Presentations

Rationale for integrating Sunitinib and PCI in ED-SCLC

 The potential for synergy between PCI and sunitinib is supported by both preclinical and clinical reports.

 It has previously been established that small cell lung cancer expresses vascular endothelial growth factor ( VEGF ) receptors and that VEGF is required for the development of brain metastases .  In murine models , the delivery of antiangiogenic agents alone to the brain has been shown to slow the growth of brain metastases . Sunitinib seems to have a “single-agent activity” against brain metastases also in human models.